Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones(University of Padua), Gideon M. Hirschfield(University of Birmingham), Norman Gitlin(Atlanta Gastroenterology Associates), Hemant Shah(University Health Network), John M. Vierling, Christopher L. Bowlus(University of Padua), George Mells(University of Cambridge), Marek Hartleb(Medical University of Silesia), Virginia Clark, Charles A. McWherter(CymaBay Therapeutics (United States)), Stuart C. Gordon(Henry Ford Health System), Alexandra Steinberg(CymaBay Therapeutics (United States)), Ewa Janczewska, Pol Boudes(CymaBay Therapeutics (United States)), B. Freilich(Kansas City Research Institute), Cynthia Levy(University of Miami), Peter Buggisch(Universität Hamburg), Andreas E. Kremer(Friedrich-Alexander-Universität Erlangen-Nürnberg), Mark G. Swain(University of Calgary), David Sheridan(University Hospitals Plymouth NHS Trust), Joseph A. Odin(Icahn School of Medicine at Mount Sinai), Fedja A. Rochling(University of Nebraska Medical Center), Mónika Varga(CymaBay Therapeutics (United States)), Yun‐Jung Choi(CymaBay Therapeutics (United States)), Mark Jonas(Ohio Gastroenterology and Liver Institute), John H. Smith(Digestive & Liver Disease Specialists), M A Wörns(Johannes Gutenberg University Mainz), David Bernstein(University of Florida), Bruce R. Bacon(Saint Louis University), Michael Galambos, Yvonne Döerffel(Charité - Universitätsmedizin Berlin), Heinz Hartmann(Praxis für Humangenetik), Harinder Chera(CymaBay Therapeutics (United States)), Robert L. Martin(CymaBay Therapeutics (United States)), Mitchell L. Shiffman(Bon Secours Health System)
Cited by 186
Related Papers
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
|New England Journal of Medicine|2013|1.8k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
|New England Journal of Medicine|2014|1.1k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k
Sofosbuvir for Hepatitis C Genotype 2 or 3 in Patients without Treatment Options
|New England Journal of Medicine|2013|1.1k